AU4081493A - 8-substituted anthines as phosphodiesterase inhibitors - Google Patents

8-substituted anthines as phosphodiesterase inhibitors

Info

Publication number
AU4081493A
AU4081493A AU40814/93A AU4081493A AU4081493A AU 4081493 A AU4081493 A AU 4081493A AU 40814/93 A AU40814/93 A AU 40814/93A AU 4081493 A AU4081493 A AU 4081493A AU 4081493 A AU4081493 A AU 4081493A
Authority
AU
Australia
Prior art keywords
formula
compound
pharmaceutically acceptable
group
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40814/93A
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4081493A publication Critical patent/AU4081493A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU40814/93A 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors Abandoned AU4081493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds
GB9210839 1992-05-21

Publications (1)

Publication Number Publication Date
AU4081493A true AU4081493A (en) 1993-12-13

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40814/93A Abandoned AU4081493A (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors

Country Status (10)

Country Link
EP (1) EP0641344A1 (cs)
JP (1) JPH07506591A (cs)
CN (1) CN1094046A (cs)
AU (1) AU4081493A (cs)
CA (1) CA2136196A1 (cs)
GB (1) GB9210839D0 (cs)
MX (1) MX9302957A (cs)
TW (1) TW277062B (cs)
WO (1) WO1993023401A1 (cs)
ZA (1) ZA933494B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2000068231A1 (en) * 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
NZ517546A (en) * 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60226615D1 (cs) 2001-08-28 2008-06-26 Schering Corp
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1524984A1 (en) 2002-07-29 2005-04-27 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
CN1860119A (zh) 2003-07-31 2006-11-08 先灵公司 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033922T3 (es) * 1986-08-28 1993-04-01 Sandoz Ag Procedimiento para preparar nuevos derivados de xantina.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives

Also Published As

Publication number Publication date
CA2136196A1 (en) 1993-11-25
CN1094046A (zh) 1994-10-26
JPH07506591A (ja) 1995-07-20
ZA933494B (en) 1994-03-01
EP0641344A1 (en) 1995-03-08
MX9302957A (es) 1994-05-31
TW277062B (cs) 1996-06-01
GB9210839D0 (en) 1992-07-08
WO1993023401A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
AU4081493A (en) 8-substituted anthines as phosphodiesterase inhibitors
US5981535A (en) Substituted xanthines and their use in the treatment of cerebrovascular disorders and other diseases
US5409934A (en) Xanthine derivatives
AU653364B2 (en) Xanthine derivatives
AU669702B2 (en) Enantiomeric hydroxylated xanthine compounds
AU717913B2 (en) Xanthines and their therapeutic use
JP2002508376A (ja) ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体
IE913351A1 (en) Novel compounds
JPH10508032A (ja) アリールチオキサンチン類
HK1012360B (en) Xanthinederivatives, process for their preparation and their pharmaceutical use
HK1012360A (en) Xanthinederivatives, process for their preparation and their pharmaceutical use